NodThera Doses First Patients in New GLP-1 Combo Trial
Prior clinical data for NT-0796 reported rapid reductions of about 80% in IL-6, fibrinogen, and hsCRP in patients at...
Biomea Doses First Patient in Phase I Study of Oral GLP-1
In preclinical studies, once-daily oral dosing of BMF-650 in obese cynomolgus monkeys produced dose-dependent reductions in food intake and...
IN8bio T Cell Data Shows B Cell Depletion for Autoimmune
IN8bio reported preclinical data showing that its pan-γδ T cell engager, INB-619, achieved complete B cell depletion in systemic...
Rapt Therapeutics Starts Phase 2b Trial for Food Allergies
RAPT Therapeutics has opened enrollment for prestIgE, a randomized, double-blind, placebo-controlled Phase 2b study of ozureprubart (formerly RPT904) in...
BridgeBio to Report Phase 3 Encaleret Results on Oct. 29
BridgeBio is set to release topline results from CALIBRATE, its Phase 3 study in autosomal dominant hypocalcemia type 1...
Redefining Clinical Imaging: How a Site-First Approach is Setting a New Standard for Transparency and Data Integrity
At DPHARM, we spoke with Patrick McNamara, Chief Commercial Officer at Yunu, about how the company is transforming imaging...
Creative Medical Tech Gains $4.2M in Warrant Exercise Deal
Creative Medical Technology secured approximately $4.2 million in gross proceeds through the immediate exercise of 1,116,136 previously issued, registered...
Wave’s Surging Obesity Drug Shows Promising Trial Results
Single-dose WVE-007 reduced circulating Activin E by 56% at 75 mg, 75% at 240 mg, and 85% at 400...
Wave Life Sciences Sees Positive Data for Obesity Drug WVE-007
Wave reported dose-dependent, single-dose reductions in circulating Activin E at day 29 in its INLIGHT obesity study: 85% at...
Tectonic’s TX45 Shows Positive Data in Phase 1b PH Trial
TX45 produced acute, directionally favorable hemodynamic and echocardiographic changes in PH-HFrEF after a single intravenous dose: pulmonary capillary wedge...